Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
Panelists discuss the optimal timing of chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), which requires careful evaluation of patient fitness, disease burden, prior treatment response, and logistical factors. Key considerations include performance status, comorbidities, disease aggressiveness, and the availability of bridging therapy. Treatment decisions should be individualized based on patient-specific risk factors, prior therapy outcomes, and care goals while balancing the potential benefits and risks across different lines of treatment.
Video content above is prompted by the following:
- What factors should be considered when determining the optimal timing and patient selection for advanced therapies like chimeric antigen receptor T-cell therapy in relapsed/refractory DLBCL?
- How might you consider treatment decisions for patients across different risk profiles and lines of therapy?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
